Platelets, plasma, and red blood cells
Since its inception in 1991, Concord, California's Cerus Corporation (CERS) has focused nearly all of its resources into the development of the Intercept Blood System. Donated blood undergoes intense screening for every conceivable pathogen before separated into red blood cells [RBCs], plasma, platelets, and numerous other products. The Intercept Blood System is intended to stop the proliferation of any pathogens that pass the screening process, or find their way into blood products during the manufacturing process.
Stops all gene expression, just add light
Cerus's Intercept Plasma and Platelet Systems are based on amotosalen HCL, a synthetic version of naturally occurring compounds that insert themselves into DNA. When exposed to ultraviolet radiation amotosalen...